Vanita Noronha, Nandini S Menon, Vijay Maruti Patil, M V Chandrakanth, Sucheta More, Aditya Dhanawat, Oindrila Roy Chowdhary, Ajaykumar Chandrabhan Singh, Supriya Goud, Srushti Shah, Naveen Karuvandan, Kunal Naishadh Jobanputra, Darshit Kalpeshkumar Shah, Minit Jalan Shah, Rupjyoti Sarma, Dhwaniben Patel, Ritam Joarder, Prashant Kumar, Anupa John, Jaspreet Kaur, Saurabh Bagra, Nilendu Purandare, Amit Janu, Abhishek Mahajan, Kumar Prabhash
INTRODUCTION: The outcomes in advanced NSCLC have improved owing to the availability of more effective systemic and improved supportive care. This has increased the number of patients who seek treatment in the third line and beyond setting. We conducted this study to compare the quality of life (QoL), toxicity, and outcomes in patients receiving chemotherapy and EGFR tyrosine kinase inhibitors (TKIs) in this setting. METHODS: In this phase 3, randomized, open-label study, patients with stage III or IV NSCLC with disease progression on at least two prior lines of chemotherapy, with a life expectancy of at least 3 months, without prior EGFR TKI exposure, and stable brain metastases (if any) were included...
January 2024: JTO clinical and research reports